Exicure, Inc. (Nasdaq: XCUR) reported financial results for Q3 2025, with cash and cash equivalents at $4.4 million, down from $12.5 million in December 2024. R&D expenses were $0.9 million due to acquiring GPCR USA. G&A expenses were $1.5 million, with a $4,000 loss from the sale of assets. Net loss was $2.4 million.

Management stated that existing cash isn’t enough to fund operations and additional financing is needed. Exicure, Inc. is exploring strategic alternatives to maximize shareholder value. The company’s lead program aims to improve stem cell mobilization in various diseases. Additional financing is crucial for operations and exploring strategic opportunities. Forward-looking statements were made regarding the company’s future plans and objectives.

Exicure, Inc.’s unaudited balance sheet showed cash and cash equivalents at $4,438 as of September 30, 2025, with total assets at $15,267. Liabilities stood at $8,340, and stockholders’ equity was $6,927. The unaudited statement of operations for Q3 2025 reported a net loss of $2,437, with operating expenses mainly from R&D and G&A costs. The company is focused on maximizing shareholder value and pursuing strategic alternatives.

Read more at GlobeNewswire: Exicure, Inc. Reports Third Quarter 2025 Financial Results